June 1, 2022 21:11
Today, Wednesday, the German “Biontech” pharmaceutical company expected to reach “in the coming weeks” the results of its current clinical studies on the effectiveness and safety of Corona vaccines that have been modified to be candidates to combat the Omicron mutant.
During the company’s virtual general assembly, the founder and president of “Biontech” Ugur Sahin announced that it is expected that these results will be discussed “urgently” with the authorities concerned with issuing licenses, noting that the authorities will determine based on these data the subsequent procedure that will be required to issue a possible license for the active substance. modified.
On the other hand, Shaheen said that the order books for the Corona vaccine, developed by “Biontech” and its American partner, “Pfizer”, are well filled, noting that the volume of orders for this year is about 2.4 billion doses (according to the situation at the end of last April).
Shaheen expressed his belief that the success of the Corona vaccine has turned “Biontech” into a “power center for immunotherapy” and said that there is a possibility to apply many products in the field of fighting cancer and infectious diseases during the next three to five years.
For his part, the company’s financial director, Jens Holstein, confirmed to the shareholders participating in the assembly via video, expectations that the company’s total sales will range between 13 and 17 billion euros this year.
It is noteworthy that “Biontech”, headquartered in the city of Mainz, western Germany, has increased the number of its employees to more than 3000 people worldwide.
Source: db a
#Announcing #results #study #Omicron #vaccine
